Fig. 3.

Association between baseline nectin expression and response to combo-immunotherapy. A Fresh tumor tissues and associated blood samples for each patient (n = 16) were stained and then analysed by flow cytometry. B Box plots showing the frequency of CD226⁺, CD226⁻, TIGIT⁺ and TIGIT⁻ populations within CD4 T cells and CD8 T cells in patients’ blood and tumor. C, D Box plots showing the frequency of CD226⁺, CD226⁻, TIGIT⁺ and TIGIT⁻ populations within CD4 T cells and CD8 T cells in patients’ blood (C) and tumor (D) according to responder (R) or non-responder (NR) status. E Box plots showing the median fluorescence intensity (MFI) of CD96 marker in CD4 TILs and CD8 TILs in patient tumors according to responder (R) or non-responder (NR) status. F, G Box plots showing the median fluorescence intensity (MFI) of CD96 marker in each cell subtype expressing or not TIGIT: TIGIT⁻, TIGIT^low and TIGIT^high in CD4 TILs (F) and CD8 TILs (G) in patient tumors according to responder (R) or non responder (NR) status. Statistical difference was determined by a Mann–Whitney test. ns not significant, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001